Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration

14-Nov-2017 Intellasia | BusinessWire | 9:44 PM Print This Post
  • Scope of partnership expanded, including additional research capacity
  • Collaboration extended until 2026

BENGALURU, India–(BUSINESS WIRE)–#BBRC–Syngene International, India’s largest contract research organization,
today announced that it has expanded its ongoing collaboration with
Bristol-Myers Squibb. The next phase of the partnership will see the
addition of a new facility to support future Bristol-Myers Squibb
research and development operations, an expansion of the team and the
extension of the existing agreement through 2026. The expansion will
enable the two companies to undertake a greater range of scientific
research and development for pharmaceuticals across a broader range of

Syngene and Bristol-Myers Squibb have worked together since 1998. The
research campus, known as Biocon BMS Research Center (BBRC), Syngene’s
first dedicated R&D Center, was established in 2007, which was
subsequently renewed through 2020 and now has been further extended
through 2026. It is the largest research and development facility for
Bristol-Myers Squibb outside of the United States and plays an integral
part within their global research and development network.

Since its inception, BBRC has contributed to the discovery and
pre-clinical development of numerous drug candidates for further study,
as well as generated data that has led to multiple patent filings around
the world. It has also played a key role in reducing the time and costs
associated with advancing new compounds to first-in-human studies for
Bristol-Myers Squibb.

As part of the expansion, Syngene will set up a new dedicated facility
spread across 25,000 sq. ft. of laboratory and office space for
Bristol-Myers Squibb. This facility will house an additional team of 75
Syngene scientists who will work exclusively in support of Bristol-Myers

“We are proud of how the partnership with Syngene and the BBRC has
said Carl Decicco, Ph.D., Head of Discovery, Bristol-Myers
Squibb. “At its inception, it was thought that BBRC would be a fast,
nimble organization that could partner closely with our R&D organization
to accelerate the development of Bristol-Myers Squibb’s pipeline and the
partnership has exceeded all expectations.”

Commenting on the extension of collaboration, Jonathan Hunt, Chief
Executive Officer, Syngene International, said, “We are very excited
about the potential that this expansion to our collaboration with
Bristol-Myers Squibb brings in delivering innovative scientific
solutions to address disease globally. We consider our work with
Bristol-Myers Squibb to be a ‘flagship’ relationship. They understand
and appreciate the exceptional quality of science that is accessible at
Syngene, and have been consistently generous in sharing their own
expertise to nurture young Indian talent for the betterment of the
collaboration and for patients everywhere.”

BBRC provides integrated services supporting Discovery, Translational
Sciences and Product Development functions for Bristol-Myers Squibb.

About Syngene

Syngene International Limited is India’s largest Contract Research
Organization providing integrated discovery and development services for
novel molecules across multiple platforms including small molecules,
large molecules, Antibody-Drug Conjugates and Oligonucleotides. It
brings together a state-of-the-art infrastructure spread across 1.3 Mn
sq. ft and a highly experienced team of about 3100 scientists, to help
R&D focused organizations achieve better R&D efficiency and reduce
development time. In FY2017, Syngene serviced 293 clients including 8 of
the top 10 global pharma companies as well as industry leaders in
segments like biotechnology, nutrition, animal health, consumer goods
and specialty chemicals. For more details, visit


Syngene International Limited
Sandeep Nair
P: +91 80 6775 8775
+91 88843 67776
Fax: +91 80 2852 3423
[email protected]


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.